Search results for "thérapie"
showing 10 items of 41 documents
Overall survival impact of BEACOPP versus ABVD in advanced hodgkin lymphoma: a pooled analysis of 4 randomized trials
2016
IF 6.671; International audience
Study of mechanisms of action of an immunotherapy by triacyl lipid A in humans
2013
Immunotherapy acting at the primary tumor site and preventing the development of metastases is one of the strategies for treatment of patients with cancer. To improve the efficiency of the latter, it is necessary to understand how it induces tumor cell death. In the laboratory, it was observed the cure of PROb tumors in rats BDIX by the triacyl lipid A. It has been shown that this effect involved the immune system involving interactions with TLRs present in many tumor cells and innate immunity cells such as neutrophils.In this work, we investigated the possible involvement of neutrophils in the antitumor activity of triacyl lipid A in humans.In a Phase 1 study in patients with refractory so…
Etude des mécanismes d'action d'une immunothérapie par un lipide A, seul ou associé à l'oxaliplatine, dans des modèles de cancers coliques
2013
Colorectal cancer is a major public health concern in France. Resistance to standard chemotherapy requires development of novel therapeutic approaches. In the past decades, our team showed the immunotherapeutic properties of lipid A in a model of colon cancer in rats. 95% of rats bearing small carcinomas were cured following treatment by lipid A. The study of mechanisms underlying this immunotherapy allowed us to show that the antitumor effect of lipid A was dependent on cytotoxicity induced by granzyme B produced by intratumoral neutrophils. Indeed, we have shown that, in the tumor microenvironment, neutrophils produced granzyme B and had a pro-tumorigenic N2 phenotype. When rats were trea…
Isolated lung perfusion with chemotherapy in a pig model
2014
Introduction: The isolated lung perfusion (ILP) is an experimental technique which main objective is to deliver high dose of cytotoxic agent to the lung tissue without systemic exposure. The thesis took place in three stages: first stage, setting in vitro the chemotherapy the most efficient against colorectal cancer (CCR) cells in 30 min. Second stage, develop the ILP technique in a pig model. Third stage, lead a dose escalation study with chemotherapy by ILP.Methods: First stage, efficacy of various cytotoxic molecules against a panel of human CCR cell lines was tested in vitro after a 30-minute exposure. Second stage, pigs were treated with chemotherapy delivered by ILP during 30 minutes …
Sensibilisation aux drogues chimiothérapeutiques des tumeurs P53 négatives par activation de la phosphatase Wip1
2017
P53 is mutated in more than half of human cancers and when inactivated is often associated with a resistance to anti-cancer therapy. Our team has hown that in the case of p53-negative tumors, overexpression of Wip1 phosphatase sensitizes tumor cells to chemotherapy, while protecting normal tissues from the side effects of the treatment. To improve this strategy, two main objectives were studied. Firstly, to find a protein which can interact with Wip1 pathway and potentiate its action in this therapeutic strategy. Secondly, to find a molecule which can activate Wip1. We realized a siRNA screening of the whole human kinome to identify several kinases, whose inhibition could potentiate anti-tu…
Etude de NLRP3 dans les cellules myéloïdes immunosuppressives et les lymphocytes TCD4 dans un contexte de cancer
2013
The inflammasome NLRP3 (NOD like receptor pyd containing 3) is a multiprotein complex notably responsible for IL-1β (interleukine-1β) production, an inflammatory cytokine. Negative effects have been observed in various diseases including cancer. My thesis focuses on the effects of NLRP3 in cancer.In my first project, I studied the NLRP3 inflammasome activation in MDSC (myeloïd derived suppressor cells) after a chemotherapy treatment. Two chemotherapies, 5-Fluorouracil and Gemcitabine, are selectively able to kill MDSC, an immunosuppressive population growing during cancer evolution. MDSC’s death restores anti-tumor immunity for a while but another immunosuppressive population is established…
TRAIL signalling regulation by ezrin
2011
Background and Aim: TRAIL has sparked a growing interest in oncology due to its ability to selectively trigger cancer cell death while sparing normal cells. The Fas/actin association through ezrin, a member of the ERM protein family, has been reported to regulate early steps of Fas-mediated apoptosis. In this project, we addressed the role of ezrin regarding TRAIL-induced cell death in B lymphoma cell lines, or adherent cancer cell lines (HeLa WT, HCT116, SW480). Methods: Molecular and biochemical approaches were employed to study the relevance of ezrin and its phosphorylation status in TRAIL signaling. Results: We found that ezrin displays a negative function towards TRAIL- and Fas-mediate…
Etude du rôle d'un donneur de monoxyde d'azote (Glycéryl Trinitrate) dans la mort cellulaire immunogène induite par des chimiothérapies (FOX) et/ou r…
2017
Le cancer colorectal se situe au 3ème rang mondial des cancers les plus fréquents derrière les cancers du sein et du poumon. Dans le cas de cancer colorectal métastatique, la première ligne thérapeutique repose sur l’utilisation d’une association de chimiothérapies : le FOLFOX (acide FOLinique, 5-Fluorouracile et OXaliplatine). Malgré une forte efficacité anti-tumorale de cette combinaison, de nombreuses rechutent apparaissent nécessitant l’utilisation de nouvelles stratégies basées sur l’association du FOLFOX à d’autres agents anti-cancéreux ou stimulant le système immunitaire. Cette étude a eu comme objectif d’étudier l’effet anti-tumoral del’association du FOX (5-Fluorouracile et OXalipl…
Premesse teorico-epistemologiche per una ricerca/intervento attraverso il gruppo con genitori del Servizio Spazio Neutro
2012
International audience
Action immunitaire de chimiothérapies anticancéreuses : un exemple à travers les modes d'actions des cellules "Interferon-producting Killer Dendritic…
2009
Classical antitumoral therapies are basically perceived as a direct and lytic action of the chosen therapeutic agent against tumor cells. Nevertheless, growing evidence indicates that some anticancer strategies can work through the action of the immune system. Imatinib Mesylate (IM), a targeted drug, helped us to unravel some mechanisms of action of a natural killer sub-population: the "Interferon-producing Killer dendritic Cells" (IKDC). Thoses cells possess anti-tumoral lytic capacities, synergistically amplified by IM and interleukine (IL)-2, under the dependency of IL-15, and also antigen-presenting capability. Those cells are capable of TRAIL-mediated lysis and of antigen uptake, proce…